These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21811937)

  • 1. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.
    Harenberg J; Krämer R; Giese C; Marx S; Weiss C; Wehling M
    J Thromb Thrombolysis; 2011 Oct; 32(3):267-71. PubMed ID: 21811937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
    Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
    Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples.
    Du S; Krämer S; Giese C; Weiss C; Wehling M; Krämer R; Harenberg J
    Thromb Haemost; 2015 May; 113(5):1149-51. PubMed ID: 25608910
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
    Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
    Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
    Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
    Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of rivaroxaban in human plasma samples.
    Harenberg J; Erdle S; Marx S; Krämer R
    Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
    Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
    Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks.
    Bardy G; Fischer F; Appert A; Baldin B; Stève M; Spreux A; Lavrut T; Drici MD
    Thromb Res; 2015 Aug; 136(2):396-401. PubMed ID: 26058941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
    Gosselin RC; Francart SJ; Hawes EM; Moll S; Dager WE; Adcock DM
    Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test of the month: The chromogenic antifactor Xa assay.
    Gehrie E; Laposata M
    Am J Hematol; 2012 Feb; 87(2):194-6. PubMed ID: 22081480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays for measuring rivaroxaban: their suitability and limitations.
    Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
    Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
    Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
    Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.